

# Hepato-ST

## Supports Healthy Liver Function



The purpose of Hepato-ST is four-fold; (1) to support healthy liver function by helping normal distribution of fat in the liver, (2) to support the synthesis of phospholipids, which can help facilitate the elimination of lipids from the liver, (3) to support liver function, and (4) to support normal lipid distribution.

Hepato-ST contains nutritional compounds that have lipotropic properties. Hepato-ST can be useful in the support of a healthy liver and, in particular, support the elimination of lipids from the liver.

### General Suggested Usage:

Take as directed by your health care professional.

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world. A large contributor to the pathogenesis of NAFLD is chronic underconsumption of choline based on both functional and genetic factors. Choline has shown promise in its ability to support the healthy maintenance of liver tissue and function in those affected by NAFLD.

In addition to the powerful support offered by Choline, HepatoST also supplies progressive amounts of broccoli powder, shown to support healthy function of and protect against fatty liver changes.

Classic use of Milk Thistle Extract and and herbal promotion of drainage combine with the powerful effects offered by the anti-NAFLD components blend together herbal tradition and cutting edge application.

## Supplement Facts

Serving Size: 1 Capsule  
Servings per Container: 120

	Amount per capsule	% Daily Value
Broccoli powder	25mg	**
Carnitine (as L-Carnitine L-Tartrate)	125mg	**
Choline (as choline citrate)	100mg	**
Folate (as levomefolate calcium)	70mcg	19%
Inositol	25mg	**
L-Methionine	25mg	**
Magnesium (as magnesium citrate)	5mg	1%
Milk Thistle Extract	30mg	**
N-Acetyl L-Cysteine	25mg	**
Taurine	30mg	**
Vitamin B6 (as pyridoxal 5-phosphate)	2.5mg	125%

\*\*Daily Value (DV) not established.

**Other Ingredients:** Gelatin Capsule (Gelatin, Purified water).

**DOES NOT CONTAIN:** Sugar, wheat, casein, gluten, soy, milk, egg, yeast, preservatives, artificial flavorings, colorings, peanuts, corn, tree nuts or fish.



## Hepato-ST References

- Adzet T. Polyphenolic compounds with biological activity and pharmacological activity. *Herbs Spices Medicinal Plants* 1986;1 :167-184
- Belcaro GV, Grimaldi R, Guidi G. Improvement of capillary permeability in patients with venous hypertension after treatment with TTFCA. *Angiology* 1990; 41(7): 533-540.
- Bohm K. Choleric action of some medicinal plants. *Arzneimittel Forsch* 1959;9: 376-378.
- Bombardelli E, Cirstoni A, Lietta A. The effect of acute and chronic (Panax) ginseng saponins treatment on adrenal function; biochemical and pharmacological. *Proceedings 3rd International Ginseng Symposium*. Seoul: Korean Research Institute. 1980: p 9-16.
- Damis F, Orcel L, de Saint-Maur PP, Mamaou P. Use of a titrated extract of *Centella asiatica* in chronic hepatic disorders. *Sem Hosp Paris* 1979;55:1749-1750.
- El Zawahry MD, Kahil AM, El Banna MH. Madecassol. A new therapy for hepatic fibrosis. *Bull Soc Int Chir (Belgium)* 1975;34:296-297.
- Faber K. The dandelion *Taraxacum officinale*. *Pharmaize* 1958;13:423-436.
- Feibrich F, Koch H. Silymarin an inhibitor of lipoxygenase. *Experientia* 1979;35: 148-150.
- Fiebrich F, Koch H. Silymarin, an inhibitor of prostaglandin synthetase. *Experientia* 1979;35:150-152.
- Heafield MT, et al. Xenobiotic metabolism in Alzheimer's disease. *Neurology*. 1990;40:1095-1098.
- Hikino H, Kiso Y, Sandah S, Shoji J. Antihepatotoxic actions of ginsenosides from *Panax ginseng* roots. *Planta Medica* 1985;52: 62-64.
- Hikino H, Kiso Y, Wagner H. Antihepatotoxic actions of flavanolignans from *Silybum marianum* fruits. *Plant Medica* 1984;50:248-250.
- Jain A, Buist NR, Keenaaway NG, et al. Effect of ascorbate or N-acetylcysteine treatments in patient with hereditary glutathione synthetase deficiency. *J Pediatr* 1994; 124: 229-233.
- Johnston CJ, Meyer CG, Srilakshmi JC. Vitamin C elevates red blood cell glutathione levels in healthy adults. *Am J Clin Nutr* 1993; 58: 103-105.
- Larbovic D. Single blood test might predict drugs' effects on patients. *J NIH Res*. 1997;9:34-35
- Lee WM. Drug induced hepatotoxicity. *N Engl J Med*. 1995;333:1118-1127.
- Magil MK, et al. A multiple chemical sensitivity syndrome. *Am Acad Fam Phys*. [www.http://www.aafp.org/afp/980901ap/magil.html](http://www.aafp.org/afp/980901ap/magil.html).
- McKinnon RA, et al. Possible role of cytochromes P450 in lupus erythematosus and related disorders. *Lupus*. 1994;3:473-478.
- Meyer, et al. Genetic polymorphisms of drug metabolism. *Prog Liver Dis*. 1990; 9:307-323.
- Nassauto Get al. Effects of silibinin on biliary lipid composition. Experimental and clinical study. *J Hepatol* 1991 ;12:290-295.
- Oura H, Hiai S, Nabatini S, Nakagawa H, et al. Effect of ginseng on endoplasmic reticulum and ribosome. *Planta Medica* 1975;28:76-88.
- Oura H, Hiai S, Seno H. Synthesis and characterization of nuclear RNA induced by *Radix ginseng* extract in rat liver. *Chem Pharm Bull* 1971 ;19:1598-1605.
- Palasciano G, Protinacasa P, et al. The effect of silymarin on plasma levels of malonaldehyde in patients receiving long-term treatment of psychotropic drugs. *Curr Ther Res* 1994;55:537-545.
- Perlmutter D. Parkinson's diseases - new perspectives. *Townsend Lett. Jan* 1997: 48-50.
- Pointel JP, Boccalon H, Cloarec M, et al. Titrated extract of *Centella asiatica* (TECA) in the treatment of venous insufficiency of the lower limbs. *Angiology* 1987;38(11):46-50.
- Ridgen S, et al. Evaluation of the effect of modified entero-hepatic resuscitation program in chronic fatigue syndrome patients. *J Adv Med*. 1998;11(4):247-262.
- Ridgen S. Entero-hepatic resuscitation program for CFIDS. *The CFIDS Chronicle*. Spring 1995:46-49.
- Skvortsova RI, Pzniakovski VM, Agarkova IA. Role of vitamin factor in preventing phenol poisoning. *Vopr Pitan* 1981; 2: 32-35.
- Sonnenbicher J, Goldberg M, Hane L, et al. Stimulatory effect of silibinin on the DNA synthesis in partially hepatectomized rat livers. Nonresponsive in hepatoma and other malignant cell lines. *Biochem Pharm* 1986;35:538-541.
- Steventon GB, et al. Xenobiotic metabolism in Parkinson's disease. *Neurology*. 1989;39:883-887.
- Susnik F. Present state of knowledge of the medicinal plant *Taraxacum officinale*. *Weber. Med Razgledi* 1982;21 :323-328.
- Wagner H. Antihepatotoxic flavonoids. In: Cody V, Middleton E, Harbourne JB, eds. *Plant flavonoids in biology and medicine: biochemical, pharmacological, and structure-activity relationships*. New York, NY: Alan R Liss. 1986:p545-558
- Yammato M, Uemura T, Nakama S, et al. Serum HDL-cholesterol-increasing and fatty liver-improving action of *Panax ginseng* in high cholesterol diet-fed rats with clinical effects on hyperlipidemia in man. *Am J Chin Med* 1983;11:96-101.
- Jinsheng Yu, Sharon Marsh, Junbo Hu, Wenke Feng, and Chaodong Wu, "The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background," *Gastroenterology Research and Practice*, vol. 2016, Article ID 2862173, 13 pages, 2016. <https://doi.org/10.1155/2016/2862173>
- Chen, Yung-Ju et al. "Dietary broccoli protects against fatty liver development but not against progression of liver cancer in mice pretreated with diethylnitrosamine" *Journal of functional foods* vol. 24 (2016): 57-62.